Drug Information

Drug General Information
Drug ID
D05YTG
Former ID
DNCL001850
Drug Name
SLx-4090
Drug Type
Small molecular drug
Indication Diabetes; Dyslipidaemias; Hyperlipidaemia [ICD9: 253.5, 588.1, 272, 272.0-272.4; ICD10:E23.2, N25.1, E78] Phase 2 [524039]
Company
Surface
Structure
Download
2D MOL

3D MOL
Formula
C25H21F3N2O4
Canonical SMILES
COC1=CC=CC(=C1C2=CC=C(C=C2)C(F)(F)F)C(=O)NC3C4=CC=CC=C4<br />CCN3C(=O)O
InChI
1S/C25H21F3N2O4/c1-34-20-8-4-7-19(21(20)16-9-11-17(12-10-16)25(26,27)28)23(31)29-22-18-6-3-2-5-15(18)13-14-30(22)24(32)33/h2-12,22H,13-14H2,1H3,(H,29,31)(H,32,33)
InChIKey
QQQSLUJJBRKRHP-UHFFFAOYSA-N
PubChem Compound ID
56842149
PubChem Substance ID
135264536, 227690271, 244041830
Target and Pathway
Target(s) Microsomal triglyceride transfer protein, large subunit Target Info Modulator [531392]
KEGG Pathway Fat digestion and absorption
Reactome Chylomicron-mediated lipid transport
WikiPathways Statin Pathway
Lipid digestion, mobilization, and transport
References
Ref 524039ClinicalTrials.gov (NCT01675154) Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia. U.S. National Institutes of Health.
Ref 531392A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile. J Pharmacol Exp Ther. 2011 Jun;337(3):775-85.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.